1
|
Yan XX, Li HL, Zhang YT, Wu SY, Lu HL, Yu XL, Meng FG, Sun JH, Gong LK. A new recombinant MS-superoxide dismutase alleviates 5-fluorouracil-induced intestinal mucositis in mice. Acta Pharmacol Sin 2020; 41:348-357. [PMID: 31506573 PMCID: PMC7468365 DOI: 10.1038/s41401-019-0295-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Accepted: 08/06/2019] [Indexed: 12/21/2022] Open
Abstract
Intestinal mucositis is a common side effect of anticancer regimens that exerts a negative impact on chemotherapy. Superoxide dismutase (SOD) is a potential therapy for mucositis but efficient product is not available because the enzyme is degraded following oral administration or induces an immune reaction after intravascular infusion. Multi-modified Stable Anti-Oxidant Enzymes® (MS-AOE®) is a new recombinant SOD with better resistance to pepsin and trypsin. We referred it as MS-SOD to distinguish from other SODs. In this study we investigated its potential to alleviate 5-FU-induced intestinal injury and the mechanisms. An intestinal mucositis model was established in C57/BL6 mice by 5-day administration of 5-FU (50 mg/kg every day, ip). MS-SOD (800 IU/10 g, ig) was given once daily for 9 days. 5-FU caused severe mucositis with intestinal morphological damage, bodyweight loss and diarrhea; MS-SOD significantly decreased the severity. 5-FU markedly increased reactive oxygen species (ROS) and inflammatory cytokines in the intestine which were ameliorated by MS-SOD. Furthermore, MS-SOD modified intestinal microbes, particularly reduced Verrucomicrobia, compared with the 5-FU group. In Caco2 cells, MS-SOD (250–1000 U/mL) dose-dependently decreased tBHP-induced ROS generation. In RAW264.7 cells, MS-SOD (500 U/mL) had no effect on LPS-induced inflammatory cytokines, but inhibited iNOS expression. These results demonstrate that MS-SOD can scavenge ROS at the initial stage of injury, thus play an indirect role in anti-inflammatory and barrier protein protection. In conclusion, MS-SOD attenuates 5-FU-induced intestinal mucositis by suppressing oxidative stress and inflammation, and influencing microbes. MS-SOD may exert beneficial effect in prevention of intestinal mucositis during chemotherapy in clinic.
Collapse
|
2
|
Guaitolini E, Cavezzi A, Cocchi S, Colucci R, Urso SU, Quinzi V. Randomized, Placebo-controlled Study of a Nutraceutical Based on Hyaluronic Acid, L-carnosine, and Methylsulfonylmethane in Facial Skin Aesthetics and Well-being. THE JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY 2019; 12:40-45. [PMID: 31119010 PMCID: PMC6508480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Objective: The purpose of this study was to evaluate the efficacy and safety of a multicomponent nutraceutical (MCN) on facial skin. Methods: A randomized, placebo-controlled, single-blind trial was conducted involving two groups of female subjects affected by facial skin photoaging. For two months, volunteers took a daily dose of MCN containing 200mg of hyaluronic acid, 500mg of L-carnosine, and 400mg of methylsulfonylmethane, or a placebo. At Day 0 (T0) and Day 60 (T60), face skin hydration, elasticity, and sebometry were measured with an instrumental skin tester, and digital images of facial wrinkles were scored. A subject-based quali-/ quantitative assessment evaluating satisfaction/ quality of life was performed at T60. Results: The MCN and placebo groups each included 25 volunteers (mean ages: 49.3 and 47.8 years, respectively). After 60 days of MCN intake, glabella skin hydration and elasticity improved by 15.2 percent and 22.6 percent, respectively (p=0.03; p=0.004), glabella sebaceous secretion decreased by 24.2 percent (p=0.01), skin hydration and elasticity of the periocular area increased by 12.6 percent and 15.9 percent, respectively, and skin hydration and elasticity of the oral commissural area increased by 17.6 percent and 16 percent, respectively (p<0.001). No significant variation occurred in the placebo group. Wrinkle depth improved slightly in the MCN group (p=0.043 in the periocular area) but not in the placebo group. A slight improvement in joint pain and mucosae/ hair appearance was reported in the questionnaire in the MCN group only. Conclusions: Our results suggest that MCN is safe and effective for facial skin aesthetics and well-being.
Collapse
Affiliation(s)
- Ennio Guaitolini
- Drs. Guaitolini, Cavezzi, Colucci, Urso, and Quinzi are with Eurocenter Venalinfa in San Benedetto del Tronto (AP), Italy
- Drs. Guaitolini and Cocchi are with the Studio Medico Guaitolini-Cocchi in Novellara (RE), Italy
- Dr. Urso is with the Studio Medico Flebologico Zola in Predosa (BO), Italy
| | - Attilio Cavezzi
- Drs. Guaitolini, Cavezzi, Colucci, Urso, and Quinzi are with Eurocenter Venalinfa in San Benedetto del Tronto (AP), Italy
- Drs. Guaitolini and Cocchi are with the Studio Medico Guaitolini-Cocchi in Novellara (RE), Italy
- Dr. Urso is with the Studio Medico Flebologico Zola in Predosa (BO), Italy
| | - Stefania Cocchi
- Drs. Guaitolini, Cavezzi, Colucci, Urso, and Quinzi are with Eurocenter Venalinfa in San Benedetto del Tronto (AP), Italy
- Drs. Guaitolini and Cocchi are with the Studio Medico Guaitolini-Cocchi in Novellara (RE), Italy
- Dr. Urso is with the Studio Medico Flebologico Zola in Predosa (BO), Italy
| | - Roberto Colucci
- Drs. Guaitolini, Cavezzi, Colucci, Urso, and Quinzi are with Eurocenter Venalinfa in San Benedetto del Tronto (AP), Italy
- Drs. Guaitolini and Cocchi are with the Studio Medico Guaitolini-Cocchi in Novellara (RE), Italy
- Dr. Urso is with the Studio Medico Flebologico Zola in Predosa (BO), Italy
| | - Simone Ugo Urso
- Drs. Guaitolini, Cavezzi, Colucci, Urso, and Quinzi are with Eurocenter Venalinfa in San Benedetto del Tronto (AP), Italy
- Drs. Guaitolini and Cocchi are with the Studio Medico Guaitolini-Cocchi in Novellara (RE), Italy
- Dr. Urso is with the Studio Medico Flebologico Zola in Predosa (BO), Italy
| | - Valentina Quinzi
- Drs. Guaitolini, Cavezzi, Colucci, Urso, and Quinzi are with Eurocenter Venalinfa in San Benedetto del Tronto (AP), Italy
- Drs. Guaitolini and Cocchi are with the Studio Medico Guaitolini-Cocchi in Novellara (RE), Italy
- Dr. Urso is with the Studio Medico Flebologico Zola in Predosa (BO), Italy
| |
Collapse
|